Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Altimmune (ALT) EBITDA Margin (2016 - 2025)

Altimmune (ALT) has disclosed EBITDA Margin for 16 consecutive years, with 104884.62% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin rose 36127538.0% to 104884.62% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 214751.22% through Dec 2025, up 26038878.0% year-over-year, with the annual reading at 214751.22% for FY2025, 26038878.0% up from the prior year.
  • EBITDA Margin for Q4 2025 was 104884.62% at Altimmune, up from 379820.0% in the prior quarter.
  • The five-year high for EBITDA Margin was 728.99% in Q4 2021, with the low at 1182950.0% in Q3 2022.
  • Average EBITDA Margin over 5 years is 264861.84%, with a median of 178861.06% recorded in 2025.
  • The sharpest move saw EBITDA Margin plummeted -116173987bps in 2022, then soared 117725525bps in 2023.
  • Over 5 years, EBITDA Margin stood at 728.99% in 2021, then plummeted by -11288bps to 83015.38% in 2022, then fell by -3bps to 85191.89% in 2023, then crashed by -447bps to 466160.0% in 2024, then skyrocketed by 78bps to 104884.62% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 104884.62%, 379820.0%, and 443640.0% for Q4 2025, Q3 2025, and Q2 2025 respectively.